Related references
Note: Only part of the references are listed.Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB
Christiane Gerke et al.
PLOS ONE (2015)
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
Lee-Jah Chang et al.
LANCET (2014)
PedVacc 002: A phase I/II randomized clinical trial of MVAHIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi
Irene N. Njuguna et al.
VACCINE (2014)
DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P-falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity
Ilin Chuang et al.
PLOS ONE (2013)
Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naive Subjects Gives Comparable Immunogenicity to One Dose in ART plus Subjects
Tandakha N. Dieye et al.
PLOS ONE (2013)
A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age
Alphonse Ouedraogo et al.
PLOS ONE (2013)
The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers
Anna P. Durbin et al.
VACCINE (2013)
Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles
Janet C. Lindow et al.
VACCINE (2013)
Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in 2-to 10-year-old Human Immunodeficiency Virus-infected Children
George K. Siberry et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2012)
The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and Adolescents
Sean T. O'Leary et al.
PEDIATRICS (2012)
A Phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults
Eric A. Sheldon et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants
Veerachai Watanaveeradej et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909
Christopher J. A. Duncan et al.
PLOS ONE (2011)
Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults
Martha Sedegah et al.
PLOS ONE (2011)
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines
Rosario Z. Capeding et al.
VACCINE (2011)
A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial
Anna P. Durbin et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Vaccine Based on Adeno-Associated Virus
Eftyhia Vardas et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes in Flavivirus-Naive Adults
Dennis Morrison et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Phase I/II, Open-Label Trial of Safety and Immunogenicity of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Human Immunodeficiency Virus-Infected Adolescents
George K. Siberry et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2010)
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults
Wellington Sun et al.
HUMAN VACCINES (2009)
CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa
Etienne Karita et al.
PLOS ONE (2009)
A PHASE I-II STUDY OF LIVE ATTENUATED VARICELLA-ZOSTER VIRUS VACCINE TO BOOST IMMUNITY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN WITH PREVIOUS VARICELLA
Anne A. Gershon et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2009)
A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervals
Ruth D. Ellis et al.
VACCINE (2009)
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults
Kawsar R. Talaat et al.
VACCINE (2009)
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults
Ruth A. Karron et al.
VACCINE (2009)
Reduced Neutrophil Count in People of African Descent Is Due To a Regulatory Variant in the Duffy Antigen Receptor for Chemokines Gene
David Reich et al.
PLOS GENETICS (2009)
Homeostatic regulation of blood neutrophil counts
Sibylle von Vietinghoff et al.
JOURNAL OF IMMUNOLOGY (2008)
Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers
Peter F. Wright et al.
VACCINE (2008)
Safety and immunogenicity of recombinant low-dosage HIV-1 a vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa
Walter Jaoko et al.
VACCINE (2008)
HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers
Elizabeth J. McFarland et al.
AIDS (2006)
The live attenuated dengue serotype 1 vaccine rDEN1Δ30 is safe and highly immunogenic in healthy adult volunteers
Anna P. Durbin et al.
HUMAN VACCINES (2006)
Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)
Violette Sanchez et al.
VACCINE (2006)
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults
S Kitchener et al.
VACCINE (2006)
Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults - Phase 1 trial
KL Kotloff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-Infected women
CK Cunningham et al.
CLINICAL INFECTIOUS DISEASES (2001)
Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus - poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans
N Kanesa-thasan et al.
VACCINE (2000)
Share Paper
